Pharmacological interventions in dysthymia

European Psychiatry

Volumn 11, Issue SUPPL. 3, 1996, Pages 129s-133s

  Lecrubier, Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

amisulpride; antidepressant; controlled trials; dysthymia

Indexed keywords

AMISULPRIDE; IMIPRAMINE; ISOCARBOXAZID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DYSTHYMIA; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; TREMOR; XEROSTOMIA;

EID: 0029884906     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-9338(96)85187-X     Document Type: Article

References (30)

1. Akiskal HS, Rosenthal TL, Haykal RF et al. Characterologic depressions: clinical and sleep EEG findings separating "subaffective dysthymias" from "character spectrum disorders". Arch Gen Psychiatry 1980;37:777-83
2. Boyer P, Lecrubier Y, Puech A et al. Treatment of dysthymia with low doses of amisulpride vs amineptine. Clin Neuropharmacol 1992;15:1B-23B
3. Bronisch T, Wittchen H, Krieg C et al. Depressive neurosis. Acta Psychiatr Scand 1985;71:237-48
4. Davidson JRT, Giller EL, Zisook S and Overall JE. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatr 1988;45:120-7
5. Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972;26:57-63
6. Golberg DP, Lecrubier Y. Form and frequency of mental disorders across centres. In: Üstün TB, Sartorius N, eds. Mental illness in general health care. An international study. New York: John Wiley & Sons Ltd, 1995;323-34
7. Guyon A, Assouly-Besse F, Biala G, Puech AJ, Thiebot MH. Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats. Psychopharmacology 1993; 110:460-6
8. Keller MB, Shapiro RW. "Double depression": superimposition of acute depressive episodes on chronic depressive disorders. Am J Psychiatr 1982;139:438-42
9. Keller MB, Lavori PW, Endicott J et al. "Double depression": two-year follow-up. Am J Psychiatr 1983;140:689-94
10. Klein DF. Pathophysiology of depressive syndromes. Biol Psychiatry 1974;8:119-20
11. Klein DF, Gittelman R, Quitkin FM, Rifkin A. Diagnosis and drug treatment of psychiatric disorders: adults and children. Ed 2. Baltimore: Williams & Wilkins, 1980
12. Kocsis JH, Frances AJ, Mann JJ et al. Imipramine for the treatment of chronic depression. Psychopharmacol Bull 1985;21:698-700
13. Kocsis JH, Thase ME, Koran L, Halbreich U, Yonkers K. Pharmacotherapy of "pure" dysthymia: sertraline vs imipramine and placebo. VIIth ECNP. Jerusalem, Israel: Eds Elsevier, 16-22 October 1994;204
14. Lecrubier Y. Les différentes mesures. Présentation d'un instrument de mesure clinique. In: Widlöcher D, ed. Le Ralentissement dépressif. Paris: Collection Nodules PUF, 1983;26-40
15. Lecrubier Y, Puech AJ, Aubin F, Boyer P, Deyrieux B. Improvement by amisulpride of the negative syndrome in non-psychotic subjects. A preliminary study. Psychiatry Psychobiol 1988; 3(5):329-33
16. Lecrubier Y. Thymasthenia: clinical and pharmacological aspects. "Psychiatry in the 80s." Excerpta Medica 1989;7(3):5-6
17. Lecrubier Y, Puech AJ, Boyer P. The Contribution of Neuropharmacology to the Understanding of III-Defined Psychological Disorders. In: Sartorius N, Goldberg D, de Girolamo G, Costa e Silva JA, Lecrubier Y, Wittchen, eds. Psychological Disorders in General Medical Settings. New York: Hogrefe & Huber Publishers, 1990;98-110
18. Lecrubier Y, Boyer P, Puech AJ, Aubin F, Rein W. Amisulpride versus imipramine and placebo in dysthymia. CINP. Nice. France. 29 June - 2 July, 1992
19. Lecrubier Y, Pedarriosse AM, Payan C et al. Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression. Acta Psychiatr Scand 1995;92:260-5
20. Paykel ES, Rowan PR, Parker RR et al. Response to phenelzine and amitriptyline in subtypes of depressed outpatients. Arch Gen Psychiatr 1982;39:1041-9
21. Puech AJ, Simon P, Boissier JR. Benzamides and classical neuroleptics: comparison of their actions using 6-apomorphine-induced effects. Eur J Pharmacol 1978;50:291-300
22. Rounsaville BJ, Sholomskas D, Prussof BA. Chronic mood disorders in depressed outpatients. J Affective Disord 1980;2:73-88
23. 3 receptors. XIXth CINP congress. Washington DC:Eds Elsevier,June 27-July 1, 1994;242s
24. Schildkraut JJ, Klein DF. The classification and treatment of depressive disorder. In: Shader RI, ed. Manual of psychiatric therapeutics. Boston: Little Brown, 1975
25. 3) as a target for neuroleptics. Nature 1990;347:146-50
26. Tyrer P. Towards rational therapy with monoamine oxidase inhibitors. Br J Psychiat 1976;128:354-60
27. Versiani M. Pharmacotherapy of dysthymia: a control led study with Imipramine, Moclobemide or Placebo. Neuropsychopharmacol 1994;10:298s
28. Weissman MM and Klerman GL. The chronic depressive in the community: under-recognized and poorly treated. Compr Psychiatr 1977;18:523-31
29. West ED, Dally PJ. Effect of iproniazide in depressive syndromes. Br Med J 1959;1:1491-4
30. Widlöcher D, Allilaire JF, Guérard des Lauriers A, Lecrubier Y. L'Amisulpride, neuroleptique et antidéficitaire. Encéphale 1990;XVI:159-63